Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

NCT07369986 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Cancer
Immunotherapy
Mismatch Repair Deficiency

Interventions

DRUG: Iparomlimab and Tuvonralimab (QL1706)

Sponsor

Women's Hospital School Of Medicine Zhejiang University